• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Altimmune Inc.

    5/13/26 4:17:43 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALT alert in real time by email
    S-8 1 alt-20260513xs8.htm S-8

    As filed with the Securities and Exchange Commission on May 13, 2026

    ​

    Registration No. 333-

    ​

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

    ALTIMMUNE, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware

     

    20-2726770

    (State or other jurisdiction

    of incorporation)

     

    (I.R.S. Employer

    Identification No.)

     

     

    910 Clopper Road Suite 201S 

    Gaithersburg, Maryland 

     

    20878

    (Address of principal executive offices)

     

    (Zip Code)

    ​

    ALTIMMUNE, INC.

    2019 EMPLOYEE STOCK PURCHASE PLAN

    (Full Title of the Plan)

     

    Jerome Durso

    Chief Executive Officer

    Altimmune, Inc.

    910 Clopper Road, Suite 201S

    Gaithersburg, Maryland

    Telephone: (240) 654-1450

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

    Joseph Theis, Jr.

    Justin Anslow

    Goodwin Procter LLP

    100 Northern Ave

    Boston, MA 02210

    Telephone: (617) 570-1000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

    Large accelerated filer

     

    ¨

     

    Accelerated filer

     

    ¨

     

     

     

     

    Non-accelerated filer

     

    x  

     

    Smaller reporting company

     

    x  

     

     

     

     

     

     

     

     

    Emerging growth company

     

    ¨

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ¨

     

    ​

    ​


    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 registers an additional 705,327 shares of the Registrant’s common stock, $0.0001 par value per share (“Common Stock”) under the Altimmune, Inc. 2019 Employee Stock Purchase Plan, as amended (the “2019 ESPP”). The additional shares are of the same class as other securities relating to the 2019 ESPP for which the Registrant’s registration statement filed on Form S-8 filed with the Securities and Exchange Commission on April 4, 2019 (Registration No. 333-230722) (the “Registration Statement”), is effective. The information contained in the Registration Statement is hereby incorporated by reference pursuant to General Instruction E.

    ​

    ​


    Part II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    See the Exhibit Index below for a list of exhibits filed as part of this registration statement on Form S-8, which Exhibit Index is incorporated herein by reference.

     

    EXHIBIT INDEX

     

    Exhibit

     

     

    No.

     

    Description

     

     

     

    4.1

     

    Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to the Current Report on Form 8-K (File No. 001-32587) filed with the Securities and Exchange Commission on October 18, 2017).

     

     

     

    4.2

     

    Certificate of Amendment to Amended and Restated Certificate of Incorporation regarding a reverse stock split (incorporated by reference to the Current Report on Form 8-K (File No. 001-32587) filed with the Securities and Exchange Commission on September 13, 2018).

     

     

     

    4.3

     

    Certificate of Amendment to Amended and Restated Certificate of Incorporation regarding an increase in authorized shares (incorporated by reference to the Current Report on Form 8-K (File No. 001-32587) filed with the Securities and Exchange Commission on September 13, 2018).

    ​

    ​

    ​

    4.4

     

    Certificate of Amendment to Amended and Restated Certificate of Incorporation regarding an increase in authorized shares (incorporated by reference to the Current Report on Form 8-K (File No. 001-32587) filed with the Securities and Exchange Commission on April 16, 2026).

     

     

     

    4.5

     

    Amended and Restated Bylaws of the Registrant (incorporated by reference to the Current Report on Form 8-K (File No. 001-32587) filed with the Securities and Exchange Commission on October 18, 2017).

    ​

    ​

    ​

    5.1*

     

    Opinion of Goodwin Procter LLP.

     

     

     

    23.1*

     

    Consent of Ernst & Young LLP, independent registered public accounting firm.

     

     

     

    23.2*

     

    Consent of Goodwin Procter LLP (included in Exhibit 5.1).

     

     

     

    24.1*

     

    Power of Attorney (included on signature page).

     

     

     

    99.1

     

    2019 Employee Stock Purchase Plan (incorporated by reference to the Registration Statement on Form S-8 (File No. 333-230722) filed with the Securities and Exchange Commission on April 4, 2019).

     

     

     

    107*

     

    Filing Fee Table

    ​

     

    *

    Filed herewith

    ​

    ​

    ​


    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Gaithersburg, State of Maryland, on the 13th day of May, 2026.

     

     

    ALTIMMUNE, INC.

     

     

     

     

     

     

    By:  

    /s/ Jerome Durso

     

     

     

    Jerome Durso

     

     

     

    President and Chief Executive Officer

     

    POWER OF ATTORNEY AND SIGNATURES

     

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Jerome Durso and Gregory Weaver as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following person in the capacities and on the date indicated.

     

    Name

    Title

    Date

     

     

     

    /s/ Jerome Durso

    Jerome Durso

    Chairman of the Board of Directors, President and Chief Executive Officer

    (Principal Executive Officer)

    May 13, 2026

     

     

     

    /s/ Gregory Weaver

    Gregory Weaver

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

    May 13, 2026

     

     

     

    /s/ John Gill

    John Gill

    Director

    May 13, 2026

     

     

     

    /s/ Philip Hodges

    Philip Hodges

    Director

    May 13, 2026

     

     

     

    /s/ Diane Jorkasky, M.D.

    Diane Jorkasky, M.D.

    Director

    May 13, 2026

     

     

     

    /s/ Teri Lawver

    Teri Lawver

    Director

    May 13, 2026

     

     

     

    /s/ Wayne Pisano

    Wayne Pisano

    Director

    May 13, 2026

    ​

    ​

    ​

    /s/ Mitchel Sayare, Ph.D.

    Mitchel Sayare, Ph.D.

    Director

    May 13, 2026

     

     

     

    /s/ Klaus O. Schafer, M.D.

    Klaus O. Schafer, M.D. 

    Director

    May 13, 2026

     

     

     

    /s/ Catherine Sohn, Pharm D.

    Catherine Sohn, Pharm D. 

    Director

    May 13, 2026

     

     

     

    ​

    ​

    ​

    ​


    Get the next $ALT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALT

    DatePrice TargetRatingAnalyst
    4/24/2026$2.50Sell → Neutral
    Goldman
    3/18/2026$12.00Buy
    Truist
    1/28/2026$20.00Overweight
    Barclays
    7/10/2025$1.00Sell
    Goldman
    2/28/2025Mkt Perform
    William Blair
    1/8/2025$18.00Buy
    Stifel
    11/12/2024$26.00Buy
    UBS
    4/29/2024Buy → Neutral
    Guggenheim
    More analyst ratings

    $ALT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Altimmune Inc.

    SCHEDULE 13G/A - Altimmune, Inc. (0001326190) (Subject)

    5/15/26 4:15:13 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Altimmune Inc.

    S-8 - Altimmune, Inc. (0001326190) (Filer)

    5/13/26 4:17:43 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Altimmune Inc.

    10-Q - Altimmune, Inc. (0001326190) (Filer)

    5/13/26 4:13:42 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Altimmune upgraded by Goldman with a new price target

    Goldman upgraded Altimmune from Sell to Neutral and set a new price target of $2.50

    4/24/26 7:59:47 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Altimmune with a new price target

    Truist initiated coverage of Altimmune with a rating of Buy and set a new price target of $12.00

    3/18/26 4:00:13 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Altimmune with a new price target

    Barclays initiated coverage of Altimmune with a rating of Overweight and set a new price target of $20.00

    1/28/26 7:15:18 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026

    "Best of EASL" oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors PERFORMA Phase 3 trial to further evaluate the broad metabolic and liver-related effects of pemvidutide GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new 48-week data from the IMPACT Phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced elevated lipids while improving multiple cardiometabo

    5/28/26 11:00:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune to Participate in Upcoming Investor Conferences

    GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences: 2026 Jefferies Global Healthcare ConferenceThursday, June 4, 2026Fireside chat at 12:50 p.m. ETNew York, NY Goldman Sachs 47th Annual Global Healthcare Conference Wednesday, June 10, 2026Fireside chat at 8:00 a.m. ETMiami Beach, FL A webcast of the fireside chats will be available via the Events section of the Altimmune website. About AltimmuneAltimmune is a late clinical-stage biopharmaceutical co

    5/27/26 8:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026

    Concurrent improvement across key non-invasive tests underscores convergence of pemvidutide effects on MASH disease activity and fibrosis AI-based digital pathology analyses further demonstrate antifibrotic effects of pemvidutide at 24 weeks GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new analyses of data from the IMPACT Phase 2b trial demonstrated that treatment with pemvidutide, an investigational, balanced 1:1 glucagon/GLP-1 dual receptor agonist, is associated with concurrent improvements across multiple non-invasive tes

    5/27/26 8:00:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Lawver Teri L

    4 - Altimmune, Inc. (0001326190) (Issuer)

    5/1/26 4:23:16 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Sohn Catherine A.

    4 - Altimmune, Inc. (0001326190) (Issuer)

    5/1/26 4:20:49 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Jorkasky Diane

    4 - Altimmune, Inc. (0001326190) (Issuer)

    5/1/26 4:18:40 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Weaver Gregory L bought $17,700 worth of shares (5,000 units at $3.54), increasing direct ownership by 22% to 28,078 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:05:04 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Durso Jerome Benedict bought $70,790 worth of shares (20,000 units at $3.54), increasing direct ownership by 160% to 32,500 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:00:05 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Pisano Wayne bought $20,410 worth of shares (5,000 units at $4.08), increasing direct ownership by 59% to 13,498 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    1/9/26 4:10:05 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Leadership Updates

    Live Leadership Updates

    View All

    Altimmune Announces CEO Transition and Succession Plan

    Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and metabolic diseases, today announced a CEO succession plan under which Vipin Garg, Ph.D. will step down as the Company's President and Chief Executive Officer effective January 1, 2026. Altimmune's Chairman of the Board, Jerry Durso, will assume the role of President and Chief Executive Officer and retain his position as Chairman. To facilitat

    12/1/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

    Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025. Dr. Arbet-Engels joins the Company with more than 30 years of experience spanning industry, academia and private practice, and will lead the ongoing c

    9/29/25 7:30:11 AM ET
    $ALT
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

    GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M. Richardson to the role of Chief Commercial Officer, effective September 16, 2025. Ms. Richardson joins the Company with more than 30 years of experience in sales and marketing, commercial, corporate and business development across a range of therapeutic areas, including metabolic disease, hepatology, cardiovascular and addiction medicine. During her career, she has led multiple product launches, built successful commercial franchises

    9/15/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

    SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

    11/14/24 11:58:56 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

    SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

    10/17/24 11:16:51 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

    SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

    10/16/24 4:21:16 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Financials

    Live finance-specific insights

    View All

    Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

    GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on May 13 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the

    5/6/26 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

    GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its fourth quarter 2025 financial results on Thursday, March 5, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on t

    2/26/26 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

    Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint Additional weight loss from 24 to 48 weeks with 1.8 mg dose, without plateauing Favorable tolerability profile of pemvidutide preserved at 48 weeks, reinforced by low treatment-related discontinuation rate End-of-Phase 2 meeting with FDA supports advancing to registrational Phase 3 trial in MASH patients with moderate to advanced liver fibrosis Conference call to be held today at 8:00 a.m. ET GAITHERSBURG, Md., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing thera

    12/19/25 6:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care